EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy

Ju Young Bae iD, Dae Yong Park, Soumya Banna, Jiun-Ruey Hu iD, Amr Saleh, Mamas A Mamas, Robert L McNamara, Michael G Nanna, John F Setaro, Luke K Kim, S Elissa Altin iD

Current Oncology · 2025

DOI: 10.3390/curroncol32090514 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Ju Young Bae und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Hospital Mortality, Pericardiocentesis, Pericardial Effusion, Neoplasms. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the high prevalence of malignant pericardial effusions (MPEs), the differences in mortality between those undergoing pericardiocentesis for MPE versus non-malignancy pericardial effusions (NMPEs) are not well characterized. To address this knowledge gap, we aim to compare clinical outcomes following pericardiocentesis among patients with MPE and NMPE.

Methods

A retrospective analysis was conducted on the US National Inpatient Sample (NIS) to identify all hospitalizations during which pericardiocentesis was performed between 1 January 2016 and 31 December 2020 (total n = 174,776,205). This cohort was further stratified based on the presence or absence of malignancy. The primary outcome of interest was in-hospital mortality. Secondary outcomes included discharge disposition (categorized as non-home discharges), length of stay, and total hospitalization costs.

Results

A total of 85,125 patients with pericardial effusions undergoing pericardiocentesis were identified. Patients with an MPE (n = 24,740) were younger and more likely to have a history of malnutrition, prior radiation, palliative care treatments, and do-not-resuscitate (DNR) orders compared to those with an NMPE (n = 60,385). Lung cancer was the most common malignancy (40.3%) in patients with an MPE requiring pericardiocentesis. The in-hospital mortality following pericardiocentesis was 11.8% in patients with malignancy and 8.2% in patients without (odds ratio (OR) for mortality 1.50 (95% confidence interval [CI]: 1.34–1.68, p < 0.001). Lung cancer, non-Hodgkin lymphoma, esophageal cancer, ovarian cancer, and leukemia were associated with a significantly increased risk of death during the same admission. Non-home discharge, length of stay, and total hospitalization cost were marginally greater in those with an MPE.

Conclusions

In patients undergoing pericardiocentesis, those with an MPE had significantly higher in-hospital mortality compared to those with an NMPE. Additionally, the MPE group had a marginally longer length of stay and incurred higher total hospital costs. Further research is warranted to explore optimal treatment strategies for MPEs, particularly in patients with a limited life expectancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hospital MortalityPericardiocentesisPericardial EffusionNeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdult

Stichwörter der Autor:innen

malignancypericardial effusionpericardial tamponadepericardiocentesis

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY 10065, USA.
  • Department of Internal Medicine, Section of Cardiovascular Medicine, Yale New Haven Hospital, New Haven, CT 06510, USA.
  • Department of Internal Medicine, Section of Cardiovascular Medicine, University of California San Francisco, San Francisco, CA 94115, USA.
  • Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Department of Internal Medicine, St. Mary's Hospital, Trinity Health of New England, Waterbury, CT 06706, USA.
  • Keele Cardiovascular Research Group, Keele University, Newcastle ST5 5BG, UK.

ORCID-Profile: Ju Young Bae, Jiun-Ruey Hu, S Elissa Altin

Förderung

  • NIA NIH HHS

Zitieren

APA

Bae, J. Y., Park, D. Y., Banna, S., Hu, J. R., Saleh, A., Mamas, M. A., McNamara, R. L., Nanna, M. G., Setaro, J. F., Kim, L. K., & Altin, S. E. (2025). In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy. Current Oncology. https://doi.org/10.3390/curroncol32090514

Vancouver

Bae JY, Park DY, Banna S, Hu JR, Saleh A, Mamas MA, et al. In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy. Current Oncology. 2025. doi:10.3390/curroncol32090514

BibTeX
@article{Bae2025,
  author = {Bae, Ju Young and Park, Dae Yong and Banna, Soumya and Hu, Jiun-Ruey and Saleh, Amr and Mamas, Mamas A and McNamara, Robert L and Nanna, Michael G and Setaro, John F and Kim, Luke K and Altin, S Elissa},
  title = {In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32090514}
}
Kostenlos starten →